IP Library Granted Patent US 10,688,046
Granted Patent B2
US 10,688,046 · App. 16/676,325 · Granted Jun 23, 2020

Composition and method for vancomycin oral liquid

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,688,046
App. No.
16/676,325
Granted
Jun 23, 2020
Kind
B2
Abstract

The invention relates to stable vancomycin hydrochloride powder for oral liquid formulations. Also provided herein are methods of using vancomycin oral liquid formulations for the treatment of certain diseases such as Clostridium difficile pseudomembranous colitis and Staphylococcal enterocolitis as well as kits and related products thereof.

Claims (28)

1. A non-sterile stable liquid formulation formulated for oral administration, consisting of:

(a) 0.1-0.4% w/v citric acid,

(b) water,

(c) a sweetener that is sucralose,

(d) 0.02-0.08% w/v sodium benzoate,

(e) 20-60 mg/ml vancomycin hydrochloride, and

(f) flavoring agent,

wherein the non-sterile stable liquid formulation is homogenous and stable for at least 2 weeks at ambient and refrigerated temperature and has a pH of 2.5-4.5.

2. The liquid formulation of claim 1 , wherein the citric acid 0.12% w/v.

3. The liquid formulation of claim 1 , wherein the sucralose is 0.1-0.3% w/v.

4. The liquid formulation of claim 1 , wherein the flavoring agent is a berry flavor.

5. The liquid formulation of claim 1 , wherein the flavoring agent is 0.05% w/v.

6. The liquid formulation of claim 1 , wherein the flavoring agent is 0.01-0.1% w/v.

7. The liquid formulation of claim 1 , wherein the sodium benzoate is 0.02% w/v.

8. A method of treating Clostridium difficile pseudomembranous colitis or Staphylococcal enterocolitis in a subject comprising administering a vancomycin oral liquid composition to the subject in a therapeutically effective amount, wherein the vancomycin oral liquid composition consists of:

(a) 0.1-0.4% w/v citric acid,

(b) water,

(c) a sweetener that is sucralose,

(d) 0.02-0.08% w/v sodium benzoate,

(e) 20-60 mg/ml vancomycin hydrochloride, and

(f) flavoring agent,

wherein the vancomycin oral liquid composition is homogenous and stable for at least 2 weeks at ambient and refrigerated temperature and has a pH of 2.5-4.5.

9. The method of claim 8 , wherein the citric acid is 0.12% w/v.

10. The method of claim 8 , wherein the sucralose 0.1-0.3% w/v.

11. The method of claim 8 , wherein the flavoring agent is a berry flavor.

12. The method of claim 8 , wherein the flavoring agent is 0.05% w/v.

13. The method of claim 8 , wherein the flavoring agent is 0.01-0.1% w/v.

14. The method of claim 8 , wherein the sodium benzoate is 0.02% w/v.

Assignments (7)
CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS Recorded Mar 17, 2025
From: ARBOR PHARMACEUTICALS, LLC; AZURITY PHARMACEUTICALS, INC.; AZURITY PHARMACEUTICALS IRELAND LIMITED; SILVERGATE PHARMACEUTICALS, INC.
To: HPS INVESTMENT PARTNERS, LLC, AS ADMINISTRATIVE AGENT
Reel/Frame 070531/0487 →
RELEASE OF SECURITY INTEREST Recorded Mar 14, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.; SILVERGATE PHARMACEUTICALS, INC.; ARBOR PHARMACEUTICALS, LLC; SLAYBACK PHARMA LIMITED LIABILITY COMPANY
Reel/Frame 070521/0299 →
SECURITY INTEREST Recorded Sep 20, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 057532/0424 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 057531/0403 →
SECURITY INTEREST Recorded Apr 16, 2021
From: AZURITY PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 055938/0859 →
CHANGE OF NAME Recorded Aug 20, 2020
From: CUTISPHARMA, INC.
To: AZURITY PHARMACEUTICALS, INC.
Reel/Frame 053559/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 3, 2020
From: MUNI, INDU; MIONE, PETER; GANDHI, ANISA; LECHIARA, CRISTINA
To: CUTISPHARMA, INC.
Reel/Frame 051407/0224 →